Viewing Study NCT02187172



Ignite Creation Date: 2024-05-06 @ 3:00 AM
Last Modification Date: 2024-10-26 @ 11:27 AM
Study NCT ID: NCT02187172
Status: COMPLETED
Last Update Posted: 2019-08-15
First Post: 2014-07-08

Brief Title: Vascular Inflammation in Psoriasis-Ustekinumab VIP-U
Sponsor: University of Pennsylvania
Organization: University of Pennsylvania

Study Overview

Official Title: A PHASE IV RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS
Status: COMPLETED
Status Verified Date: 2019-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: VIP-U
Brief Summary: The VIP-U Study is a clinical trial designed to investigate the effect of ustekinumab Stelara and placebo on reducing vascular inflammation and cardiometabolic risk biomarkers in patients with moderate to severe psoriasis

This study will look for systemic vascular inflammation in study participants with a test called FDG PETCT fluorodeoxyglucose-positron emission tomographycomputed tomography The study will also look for cardiometabolic identifiers heart disease and metabolic factors in blood samples including markers of high cholesterol cholesterol efflux function the ability of cholesterol to move in the body metabolic factors and inflammation

The study will also examine the effects of ustekinumab compared to placebo on psoriasis activity severity and safety
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None